AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20406223 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 0
Study 18706417 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (subcutaneous)
Number of subjects: 104
Study 18706417 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subcutaneous)
Number of subjects: 104
Study 18706417 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (subcutaneous and intravenous)
Number of subjects: 104
Study 18706417 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (infliximab nonresponders)
Number of subjects: 104
Study 15897167 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole for 4 weeks
Number of subjects: 40
Study 15897167 — intervention group
Group type: COMPARATOR
Intervention: Griseofulvin for 6 weeks
Number of subjects: 40
Study 12698115 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (Remicade 3 mg/kg) intravenously over 2 hours
Number of subjects: 10
Study 10596306 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium levels in patients with AMI
Number of subjects: 27
Study 10596306 — intervention group
Group type: EXPERIMENTAL
Intervention: GSH-Px activity in patients with AMI
Number of subjects: 27
Study 8550048 — intervention group
Group type: EXPERIMENTAL
Intervention: D-penicillamine (DPCA)
Number of subjects: 222
Study 8550048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 8550048 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 222
Study 1647955 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetically adjusted doses of metoclopramide
Number of subjects: 28
Study 1647955 — intervention group
Group type: COMPARATOR
Intervention: Standard doses of metoclopramide adjusted to body weight
Number of subjects: 28
Study 6420904 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation anaesthetic technique (Group A)
Number of subjects: 65
Study 6420904 — intervention group
Group type: COMPARATOR
Intervention: Ketamine infusion technique (Group B)
Number of subjects: 65
Study 31640435 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib and dexamethasone (Kd56)
Number of subjects: 0
Study 31640435 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib and dexamethasone (Vd-8)
Number of subjects: 0
Study 30036412 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic steroid treatment
Number of subjects: 59
Study 30036412 — intervention group
Group type: COMPARATOR
Intervention: No steroid treatment
Number of subjects: 59
Study 26681680 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 plus oral leucovorin (LV) at 40, 50, or 60 mg according to body surface area plus LV 25 mg, both given orally twice daily for 1 week, repeated every 2 weeks (SL group)
Number of subjects: 142
Study 26681680 — intervention group
Group type: COMPARATOR
Intervention: S-1 monotherapy at the same dose as the SL group for 4 weeks, repeated every 6 weeks (S-1 group)
Number of subjects: 142
Study 26681680 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 plus oral leucovorin (LV)
Number of subjects: 142
Study 26681680 — intervention group
Group type: COMPARATOR
Intervention: S-1 monotherapy
Number of subjects: 142
Study 25234803 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium 200 μg
Number of subjects: 0
Study 25234803 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium 400 μg
Number of subjects: 0
Study 25234803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25234803 — intervention group
Group type: EXPERIMENTAL
Intervention: No event during weeks 1-12
Number of subjects: 0
Study 25234803 — intervention group
Group type: COMPARATOR
Intervention: HCRU events
Number of subjects: 0
Study 25234803 — intervention group
Group type: COMPARATOR
Intervention: EXACT-unreported events
Number of subjects: 0
Study 19543081 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 24
Study 15790675 — intervention group
Group type: EXPERIMENTAL
Intervention: Propacetamol 2 g (i.v. acetaminophen 1 g formulation) administered as a 2-min bolus injection (n=50)
Number of subjects: 175
Study 15790675 — intervention group
Group type: EXPERIMENTAL
Intervention: Propacetamol 2 g (i.v. acetaminophen 1 g formulation) administered as a 15-min infusion (n=50)
Number of subjects: 175
Study 15790675 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acetaminophen 1 g (n=50)
Number of subjects: 175
Study 15790675 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=25)
Number of subjects: 175
Study 12213864 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid hormone suppressive therapy for longer than 6 months
Number of subjects: 346
Study 12213864 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 346
Study 9140241 — intervention group
Group type: EXPERIMENTAL
Intervention: AHA-recommended technique (apex-to-anterior electrode placement, no smearing of gel between electrodes)
Number of subjects: 10
Study 9140241 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrode paddles adjacent, gel smeared between electrodes
Number of subjects: 10
Study 9140241 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-exercise measurements
Number of subjects: 10
Study 7945732 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 13
Study 7945732 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine
Number of subjects: 13
Study 3285812 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole intravenously followed by cephalexin by mouth
Number of subjects: 193
Study 3285812 — intervention group
Group type: COMPARATOR
Intervention: Methicillin intravenously followed by dicloxacillin by mouth
Number of subjects: 193
Study 11576029 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana smoking (days 1-5)
Number of subjects: 12
Study 11576029 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence from marijuana (days 6-8)
Number of subjects: 12
Study 11576029 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana smoking (days 9-13)
Number of subjects: 12
Study 11576029 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence from marijuana (days 14-16)
Number of subjects: 12
Study 29847382 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg methadone
Number of subjects: 60
Study 29847382 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg methadone
Number of subjects: 60
Study 29847382 — intervention group
Group type: COMPARATOR
Intervention: Short-duration opioids (controls)
Number of subjects: 60
Study 30400790 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior initiation only
Number of subjects: 0
Study 30400790 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior initiation + behavior maintenance
Number of subjects: 0
Study 30400790 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 27080282 — intervention group
Group type: EXPERIMENTAL
Intervention: Background volume of 5 mL/h of 0.2% ropivacaine
Number of subjects: 60
Study 27080282 — intervention group
Group type: COMPARATOR
Intervention: Background volume of 3.2 mL/h of 0.2% ropivacaine
Number of subjects: 60
Study 24552980 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume high-intensity interval training (HIT)
Number of subjects: 22
Study 24552980 — intervention group
Group type: COMPARATOR
Intervention: Higher-volume moderate-intensity continuous training (CT)
Number of subjects: 22
Study 24552980 — intervention group
Group type: COMPARATOR
Intervention: Control (CT)
Number of subjects: 22
Study 24552980 — intervention group
Group type: EXPERIMENTAL
Intervention: Control (HIT)
Number of subjects: 22
Study 22198960 — intervention group
Group type: COMPARATOR
Intervention: Conventional lectures
Number of subjects: 89
Study 22198960 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-education via videoconferencing
Number of subjects: 89
Study 20216387 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion targeting 0 ng/ml
Number of subjects: 44
Study 20216387 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion targeting 2 ng/ml
Number of subjects: 44
Study 20216387 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion targeting 4 ng/ml
Number of subjects: 44
Study 20216387 — intervention group
Group type: EXPERIMENTAL
Intervention: Effect-site propofol concentration
Number of subjects: 44
Study 20216387 — intervention group
Group type: EXPERIMENTAL
Intervention: NSRI
Number of subjects: 44
Study 17373174 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination therapy (TCT) - hydroquinone, tretinoin, and fluocinolone acetonide applied once daily
Number of subjects: 0
Study 17373174 — intervention group
Group type: COMPARATOR
Intervention: Hydroquinone alone applied twice daily
Number of subjects: 0
Study 15358840 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic manipulations (n = 43)
Number of subjects: 75
Study 15358840 — intervention group
Group type: COMPARATOR
Intervention: Instructions for physiotherapeutic exercises (n = 32)
Number of subjects: 75
Study 11250991 — intervention group
Group type: EXPERIMENTAL
Intervention: Three cycles of bleomycin, etoposide, and cisplatin (BEP) chemotherapy
Number of subjects: 812
Study 11250991 — intervention group
Group type: COMPARATOR
Intervention: Four cycles of bleomycin, etoposide, and cisplatin (BEP) chemotherapy
Number of subjects: 812
Study 11250991 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day schedule of BEP chemotherapy
Number of subjects: 812
Study 11250991 — intervention group
Group type: COMPARATOR
Intervention: 3-day schedule of BEP chemotherapy
Number of subjects: 812
Study 11250991 — intervention group
Group type: EXPERIMENTAL
Intervention: Three cycles of BEP chemotherapy
Number of subjects: 812
Study 11250991 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-day schedule of BEP chemotherapy
Number of subjects: 812
Study 9549022 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis of sodium diclofenac
Number of subjects: 40
Study 9549022 — intervention group
Group type: COMPARATOR
Intervention: Iontophoresis of sodium salicylate
Number of subjects: 40
Study 8179130 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume cycled flow generator
Number of subjects: 0
Study 8179130 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi‐level positive airway pressure
Number of subjects: 0
Study 8179130 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous ventilation
Number of subjects: 0
Study 8179130 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure
Number of subjects: 0
Study 3196094 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous repair with a prosthetic polypropylene mesh buttress
Number of subjects: 195
Study 3196094 — intervention group
Group type: COMPARATOR
Intervention: Local endogenous tissue repair
Number of subjects: 195
Study 3196094 — intervention group
Group type: EXPERIMENTAL
Intervention: Preperitoneal approach with mesh buttress
Number of subjects: 195
Study 30091545 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding (ACE)
Number of subjects: 90
Study 30091545 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface electromyogram biofeedback therapy (sEMGBF)
Number of subjects: 90
Study 30091545 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (ACE+sEMGBF)
Number of subjects: 90
Study 28832550 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BoNT) treatment
Number of subjects: 24
Study 28832550 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy controls)
Number of subjects: 24
Study 28832550 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT treatment (after 4-7 weeks and again after 11-15 weeks)
Number of subjects: 24
Study 26306437 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal tubes (LT)
Number of subjects: 313
Study 26306437 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal masks (LM)
Number of subjects: 313
Study 23195913 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial image educational strategy
Number of subjects: 127
Study 23195913 — intervention group
Group type: EXPERIMENTAL
Intervention: Teach back educational strategy
Number of subjects: 127
Study 23195913 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 127
Study 21534239 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ultrafiltration rates
Number of subjects: 32
Study 21534239 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt intake reduction
Number of subjects: 32
Study 18455576 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 14
Study 18455576 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control group)
Number of subjects: 14
Study 16533681 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based information-tool
Number of subjects: 75
Study 15381650 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG with collaterals
Number of subjects: 281
Study 15381650 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump CABG with collaterals
Number of subjects: 281
Study 15381650 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG without collaterals
Number of subjects: 281
Study 15381650 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump CABG without collaterals
Number of subjects: 281
Study 10828923 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group instructed to give an insincere effort at 50% of their perceived maximum effort
Number of subjects: 41
Study 10828923 — intervention group
Group type: COMPARATOR
Intervention: Control group instructed to give a sincere maximum effort
Number of subjects: 41
Study 10828923 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study 9750601 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrocarbonate 1% (n = 17)
Number of subjects: 66
Study 9750601 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrocarbonate 1% with adrenaline 1/200,000 (n = 17)
Number of subjects: 66
Study 9750601 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride 1% (n = 16)
Number of subjects: 66
Study 9750601 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride 1% with adrenaline 1/200,000 (n = 16)
Number of subjects: 66
Study 9750601 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 66
Study 8443358 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital luminescent radiography (DLR)
Number of subjects: 175
Study 8443358 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital luminescent radiography (DLR) with high edge enhancement
Number of subjects: 175
Study 8443358 — intervention group
Group type: COMPARATOR
Intervention: Conventional screen‐film system
Number of subjects: 175
Study 3510268 — intervention group
Group type: EXPERIMENTAL
Intervention: Decongestant-antihistamine mixture (Dimetapp)
Number of subjects: 82
Study 3510268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 29351861 — intervention group
Group type: EXPERIMENTAL
Intervention: GOALS therapy
Number of subjects: 75
Study 29351861 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 75
Study 29351861 — intervention group
Group type: COMPARATOR
Intervention: GOALS therapy and Treatment as usual
Number of subjects: 75
Study 27809773 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ECG monitoring for three weeks
Number of subjects: 110
Study 27809773 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation history
Number of subjects: 110
Study 27809773 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial volume index
Number of subjects: 110
Study 27809773 — intervention group
Group type: COMPARATOR
Intervention: Control group of age- and gender-matched patients with history of paroxysmal atrial fibrillation prior to stroke (n=55, 67±10 years, 19 female)
Number of subjects: 110
Study 24686184 — intervention group
Group type: EXPERIMENTAL
Intervention: tango+tDCS
Number of subjects: 1
Study 24686184 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 1
Study 24686184 — intervention group
Group type: COMPARATOR
Intervention: sham
Number of subjects: 1
Study 23110471 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan 40 mg, Amlodipine 10 mg, Hydrochlorothiazide 25 mg
Number of subjects: 0
Study 23110471 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan 40 mg, Amlodipine 10 mg
Number of subjects: 0
Study 23110471 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan 40 mg, Hydrochlorothiazide 25 mg
Number of subjects: 0
Study 23110471 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 10 mg, Hydrochlorothiazide 25 mg
Number of subjects: 0
Study 20207345 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation regarding thought-action fusion (TAF)
Number of subjects: 139
Study 20207345 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation regarding thoughts in general
Number of subjects: 139
Study 20207345 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 139
Study 18926223 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue (Tisseel) used as a sealant after hypospadias surgery
Number of subjects: 120
Study 18926223 — intervention group
Group type: COMPARATOR
Intervention: No sealant used (Control group)
Number of subjects: 120
Study 15830221 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg alprazolam
Number of subjects: 16
Study 15830221 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg alprazolam
Number of subjects: 16
Study 15830221 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg alprazolam
Number of subjects: 16
Study 15830221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 12613304 — intervention group
Group type: EXPERIMENTAL
Intervention: NRC + Prime & Bond + Dyract Seal (Group A)
Number of subjects: 60
Study 12613304 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional phosphoric acid + Helioseal (Group C)
Number of subjects: 60
Study 12613304 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional phosphoric acid and rinse (Group B)
Number of subjects: 60
Study 12613304 — intervention group
Group type: EXPERIMENTAL
Intervention: NRC + Helioseal (Group D)
Number of subjects: 60
Study 27093744 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 12.50 mg
Number of subjects: 0
Study 27093744 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25.00 mg
Number of subjects: 0
Study 27093744 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 6.25 mg
Number of subjects: 0
Study 27093744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7489623 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced helical CT studies
Number of subjects: 300
Study 2317417 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (0.1-0.6%)
Number of subjects: 46
Study 2317417 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.01-0.2 mg kg-1 h-1)
Number of subjects: 46
Study 2317417 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 46
Study 2317417 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 46
Study 547369 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung scans interpreted as high probability for pulmonary emboli
Number of subjects: 30
Study 547369 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung scans interpreted as low probability for pulmonary emboli
Number of subjects: 30
Study 547369 — intervention group
Group type: EXPERIMENTAL
Intervention: Radionuclide scans interpreted as nondiagnostic
Number of subjects: 30
Study 547369 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary arteriography
Number of subjects: 30
Study 31623042 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhodiola rosea + non-invasive ventilator
Number of subjects: 90
Study 31623042 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhodiola rosea
Number of subjects: 90
Study 31623042 — intervention group
Group type: COMPARATOR
Intervention: Non-invasive ventilator
Number of subjects: 90
Study 28215471 — intervention group
Group type: EXPERIMENTAL
Intervention: RP5063 15mg
Number of subjects: 234
Study 28215471 — intervention group
Group type: EXPERIMENTAL
Intervention: RP5063 30mg
Number of subjects: 234
Study 28215471 — intervention group
Group type: EXPERIMENTAL
Intervention: RP5063 50mg
Number of subjects: 234
Study 28215471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 28215471 — intervention group
Group type: EXPERIMENTAL
Intervention: RP5063 (all doses combined)
Number of subjects: 234
Study 28215471 — intervention group
Group type: EXPERIMENTAL
Intervention: RP5063
Number of subjects: 234
Study 26114240 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil 441 mg
Number of subjects: 623
Study 26114240 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil 882 mg
Number of subjects: 623
Study 26114240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 623
Study 23090718 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mood induction
Number of subjects: 0
Study 23090718 — intervention group
Group type: COMPARATOR
Intervention: Neutral mood induction
Number of subjects: 0
Study 21883353 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin once daily
Number of subjects: 61
Study 21883353 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin three times daily
Number of subjects: 61
Study 19711610 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotation-oscillation power toothbrush
Number of subjects: 171
Study 19711610 — intervention group
Group type: COMPARATOR
Intervention: Sonic power toothbrush
Number of subjects: 171
Study 17309949 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (291 patients in parallel group trials)
Number of subjects: 828
Study 17309949 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (in crossover trials, 265 patients)
Number of subjects: 828
Study 17309949 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 828
Study 15152059 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac-resynchronization therapy with a pacemaker
Number of subjects: 1520
Study 15152059 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac-resynchronization therapy with a pacemaker-defibrillator
Number of subjects: 1520